Clinical Trial

Dietary Intervention in ADPKD on Tolvaptan

Study Description

Dietary Intervention in ADPKD on Tolvaptan

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Tolvaptan has been approved in Canada as a treatment for ADPKD. Tolvaptan is an arginine vasopressin receptor antagonist which has been shown to decrease the progression of ADPKD. The main side effect of this treatment is increased urine output which leads to cessation of therapy in about 20% of patients. Low solute (low sodium, low protein) diet may alleviate this side effect. This is a single arm before / after study of dietary intervention on urine output and quality of life in ADPKD patients on a stable dose of tolvaptan.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Dietary

Low sodium, low protein dietary recommendation

Additional Information

Official Study Title

Dietary Intervention in Patients With ADPKD on Tolvaptan: Urine Output and Quality of Life

Clinical Trial ID

NCT03858439

ParticipAid ID

dPNKya